课题基金 / 基金详情

Administrative Core

Administrative Core
行政核心
批准号:
10724220
负责人:
Dan H. Barouch
金额:
$15.5万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-11 至 2028-04-30

项目摘要

项目成果

Dan H. Barouch的其他基金

相似基金

相关文献

中文摘要
翻译
集中管理对于高效的计划管理、协调和执行至关重要。核心A (行政核心)将提供所有后勤、科学、管理和财政支持,以促进 并协调本P01计划中描述的研究。核心A将确保所有项目和 核心以最佳方式运作,并遵守本提案所述的时间表和里程碑。核心A将 每两周组织一次电话会议和定期面对面会议,维护监管批准, 提供财务和后勤监督,管理分包合同,并协调与科学咨询公司的会议 董事会(SAB)和NIAID计划官员支持这一P01计划。这项详细的管理和 管理结构将确保所有研究都集中在总体目标上,以确定 针对HIV-1的bNAbs和疫苗的治疗作用机制。为了实现这些目标,我们建议 以下四个具体目标: 目标1.协调调查人员、项目和核心之间的沟通、交互和操作,以 促进本P01计划的整体进展和目标 目标2.确保和保持合规 目标3.提供详细的财务监督和管理 目标4.协调与SAB和NIAID项目官员的会议
英文摘要
Centralized administration is critical for efficient program management, coordination, and execution. Core A (Administrative Core) will provide all the logistic, scientific, managerial, and financial support to facilitate and to coordinate the studies described in this P01 program. Core A will ensure that all the Projects and Cores function optimally and adhere to the timelines and milestones described in this proposal. Core A will organize conference calls every two weeks and regular in-person meetings, maintain regulatory approvals, provide fiscal and logistic oversight, manage subcontracts, and coordinate meetings with the Scientific Advisory Board (SAB) and NIAID Program Officials to support this P01 program. This detailed administration and management structure will ensure that all the studies remain focused on the overall objective to define mechanisms of therapeutic efficacy of bNAbs and vaccines for HIV-1. To accomplish these goals, we propose the following four Specific Aims: Aim 1. To coordinate communications, interactions, and operations among investigators, Projects, and Cores to facilitate the overall progress and goals of this P01 program Aim 2. To ensure and to maintain regulatory compliance Aim 3. To provide detailed financial oversight and management Aim 4. To coordinate meetings with the SAB and NIAID Program Officials
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NHP Core
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy
CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16
海外基金